Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Teva Pharma Industries Ltd ADR (TEVA)

NYSE
Currency in USD
Disclaimer
12.86
+0.07(+0.59%)
Closed
After Hours
12.94+0.08(+0.62%)

TEVA Price Commentary

Teva 125years of developing new drugs bigest jeneic company andto be leader in biosimilar drugs.
Teva free cash flew aoutsyrnding
24.02.24 Alboteck and teva .Humira biosimilar on the top of the day.from FDA.finally.
Freecash is very intresting???
Very atractiv ???
Teva revenew my hope will be more than 17.5bilions.
If your stock is dawn its probably a time to by more.
Concidering to sturting by back .
The humira biosomilar wil be agaim changer
jaint phrma is nomber one in tell aviv stock.
Congratulation fore more than 80%.teva .
Does teva will be on the shelfh. and it so how much will be the price .
Cash flow will be great $$$????
By back or dividend.What will be the next years.
GREAY RECOVERY .
The
24.02.24 will Alboteck an Teva Recive Humira biosimilar.
The Shorts option redused sugnificalty.
Does Teva Will sturt new sucsesful sicle like the first century.good luck.
TEVA CEO WILLBRING TEV TO MULTY DEVELOP BIOSIMILAR.. PHRMA .
Does teva will by back or dividend this yeat.
Teva Develop biosimilar prodacts.partnership with other companies.
spotlight as biotechM&A obisity frenzy pick up.
HSBC strong on teva .
2025
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.